TTNP Titan Pharmaceuticals Inc.

0.17
+0.01  (+5%)
Previous Close 0.17
Open 0.17
Price To Book -4.37
Market Cap 2,751,627
Shares 15,741,571
Volume 10,102,461
Short Ratio
Av. Daily Volume 2,233,247
Stock charts supplied by TradingView

NewsSee all news

  1. Titan Pharmaceuticals and Crossroads of Southern Nevada Announce Probuphine® Availability at Crossroads Rehabilitation Facilities

    SOUTH SAN FRANCISCO, Calif., Oct. 1, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) and Crossroads of Southern Nevada ("Crossroads") rehabilitation facility today announced that Crossroads has

  2. Titan Receives Approval For Second Year Of NIDA Grant Funding For Development Of A Nalmefene Implant

    SOUTH SAN FRANCISCO, Calif., Sept. 18, 2019 /PRNewswire/ -- National Institutes of Health's National Institute on Drug Abuse (NIDA) has approved approximately $6.1 million in second-year funding for Titan's

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 treatment has commenced - noted October 11, 2017. DSMB recommended trial to continue - July 2, 2018 but further enrollment has been postponed due to lack of resources.
Ropinirole implant
Parkinson's disease
CRL issued April 30, 2013. Approved May 26 2016
Probuphine
Opioid dependence

Latest News

  1. Titan Pharmaceuticals and Crossroads of Southern Nevada Announce Probuphine® Availability at Crossroads Rehabilitation Facilities

    SOUTH SAN FRANCISCO, Calif., Oct. 1, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) and Crossroads of Southern Nevada ("Crossroads") rehabilitation facility today announced that Crossroads has

  2. Titan Receives Approval For Second Year Of NIDA Grant Funding For Development Of A Nalmefene Implant

    SOUTH SAN FRANCISCO, Calif., Sept. 18, 2019 /PRNewswire/ -- National Institutes of Health's National Institute on Drug Abuse (NIDA) has approved approximately $6.1 million in second-year funding for Titan's